The Boston-based hospital collaborated with XenoTherapeutics to create the tissue graft, known as xenoskin. The graft was genetically modified to remove a gene specific to pigs.
Massachusetts General surgeons transplanted the experimental skin graft and a cadaveric skin graft to a patient’s wound in a recent clinical trial. They removed the grafts five days later.
“Both skin grafts were adherent to the underlying wound bed and appeared indistinguishable from each other,” Massachusetts General said in a news release. “No adverse events were further observed or reported.”
Human skin grafts are costly and often in short supply. The xenografts could offer a cheaper, more widely available option for treating second- and third-degree burns.
More articles on clinical leadership and infection control:
NICU interventions boost infant vaccination rate to 93%
End may be in sight for Congo’s Ebola outbreak
Unattended ER patient dies at Pennsylvania hospital
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
